爱硒健康网丨广东爱硒健康管理有限公司官网

2022 ASCO前瞻 | 妇科肿瘤重磅研究一览

一年一度的全球肿瘤界盛会-美国临床肿瘤学会(ASCO)年会将于当地时间6月3日-6月7日召开。医脉通特梳理了妇科肿瘤领域的部分重磅研究进展。一起来看下吧!

临床科学研讨会

01

摘要号:106

一项关于AK104(抗PD1和抗CTLA4的双特异性抗体)与标准治疗联合用于持续性、复发性或转移性宫颈癌(R/M CC)一线治疗的研究

标题:A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).

报告人:王静

单位:湖南省肿瘤医院

02

摘要号:5510

开放标签、非随机、多中心的II期临床试验:贝伐珠单抗、阿替利珠单抗和rucaparib联合治疗经治的复发和进展性子宫内膜癌

标题:An open label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer.

报告人:William Hampton Bradley, MD

单位:Froedtert and the Medical College of Wisconsin

口头报告

01

摘要号:LBA5500

随机、双盲、III期ATHENA-MONO(GOG-3020/ENGOT-ov45)研究:含铂类化疗一线治疗后,rucaparib单药对比安慰剂维持治疗卵巢癌的疗效评估

标题:ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.

报告人:Bradley J. Monk, MD

单位:GOG Foundation, University of Arizona College of Medicine, Creighton University School of Medicine

02

摘要号:5501

I/II期研究:ruxolitinib与一线新辅助和术后治疗晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌

标题:A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

报告人:Charles N. Landen, MD

单位:Univ of Texas MD Anderson Cancer Ctr

03

摘要号:LBA5503

3臂、随机、开放标签的II期研究:选择性糖皮质激素受体调节剂(relacorilant)联合白蛋白结合紫杉醇治疗复发的铂类耐药卵巢癌患者的总体生存数据

标题:Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

报告人:Nicoletta Colombo, MD

单位:University of Milan-Bicocca, European Institute of Oncology (IEO) IRCCS

04

摘要号:5506

KEYNOTE-826研究的亚组分析:帕博利珠单抗联合化疗治疗持续性、复发性或转移性宫颈癌

标题:Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.

报告人:Krishnansu Sujata Tewari, MD, FACS, FACOGObstetrics & Gynecology, University of California, Irvine

单位:David Geffen School of Medicine at UCLA

05

摘要号:5507

ENGOT Cx8/GOG 3024/innovaTV 205研究:Tisotumab vedotin(TV)联合帕博利珠单抗(pembro)一线(1L)治疗复发或转移性宫颈癌(r/mCC) 的中期结果

标题:Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.

报告人:Domenica Lorusso, MD, PhD

单位:Fondazione Policlinico Gemelli IRCCS

壁报讨论

01

摘要号:5514

海报:393

随机II期NCI试验#10150研究:贝伐珠单抗和每周anetumab ravtansine或每周紫杉醇治疗铂类耐药或难治性卵巢癌

标题:A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.

报告人:Stephanie Lheureux, MD, PhD

单位:Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network

02

摘要号:5515

海报:394

II期信号寻找试验IGNITE研究:adavosertib靶向治疗复发的、人细胞周期素E1过表达伴或不伴基因扩增的高级别、浆液性卵巢癌

标题:IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.

报告人:George Au-Yeung, PhD, MBBS

单位:Department of Medical Oncology, Peter MacCallum Cancer Centre

03

摘要号:5517

海报:396

II期LIO-1研究(NCT04042116;ENGOT-GYN3/AGO/LIO):lucitanib联合纳武利尤单抗治疗晚期妇科恶性肿瘤的疗效和安全性

标题:Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).

报告人:Manish R. Patel, MD

单位:Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute

04

摘要号:5522

海报:401

II期临床试验:氟维司群联合阿贝西利新辅助治疗晚期低级别浆液性癌

标题:A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.

报告人:Lauren P. Cobb, MD

单位:Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center

壁报展示

01

摘要号:5536

海报:415

II期临床试验:安罗替尼联合信迪利单抗治疗复发的晚期宫颈癌患者的总生存结果

标题:Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.

报告人:徐沁

单位:福建省肿瘤医院

02

摘要号:5543

海报:422

II期非随机临床试验:帕博利珠单抗联合安罗替尼治疗难治性或复发性高级别浆液性卵巢癌的疗效和安全性

标题:Efficacy and safety of pembrolizumab in combination with anlotinib in the treatment of refractory or recurrent high-grade serous ovarian cancer: A phase 2 nonrandomized clinical trial.

报告人:Jianqiao Xian, MD

单位:青岛大学附属医院

03

摘要号:5551

海报:430

III期PRIME研究的亚组分析:尼拉帕利维持治疗新诊断的晚期卵巢癌患者中含铂类化疗一线治疗的疗效

标题:Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy.

报告人:尹如铁

单位:四川大学华西第二医院

04

摘要号:5591

海报:467

单臂II期试验的中期结果:卡瑞利珠单抗联合阿帕替尼治疗至少经一线治疗失败后的晚期或复发性子宫内膜癌

标题:Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.

报告人:王华英

单位:复旦大学上海医学院

05

摘要号:TPS5607

海报:480a

单臂、多中心、II期研究:安罗替尼联合卡铂/紫杉醇一线治疗和安罗替尼维持治疗新诊断的晚期卵巢癌患者

标题:Frontline therapy of anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib in patients with newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study.

报告人:Yi Jiang

单位:江苏省人民医院

备注:排名不分先后,按照摘要号进行

加硒教授微信:623296388,送食疗电子书,任选一本

分享到:更多 ()

评论 抢沙发

  • 昵称 (必填)
  • 邮箱 (必填)
  • 网址